Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bemdaneprocel - BlueRock Therapeutics

Next Previous
Drug Profile

Bemdaneprocel - BlueRock Therapeutics

Alternative Names: BRT-DA01; DA-01; MSK-DA01; Pluripotent stem cell derived dopaminergic neurons

Latest Information Update: 11 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BlueRock Therapeutics
  • Developer BlueRock Therapeutics; Memorial Sloan-Kettering Cancer Center
  • Class Gene therapies; Induced pluripotent stem cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Dopaminergic cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Parkinson's disease

Most Recent Events

  • 28 May 2025 Phase-III clinical trials in Parkinson's disease (Treatment-experienced) in USA (Intracerebral) (NCT06944522)
  • 06 May 2025 BlueRock Therapeutics plans a phase III exPDite-2 trial for Parkinson's disease (Treatment experienced) in USA (Parenteral) in May 2025 (NCT06944522)
  • 14 Jan 2025 Bayer plans phase III trial in Parkinson's disease

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top